Celebrity Inventors
Walt Disney was no Mickey Mouse inventor. He devised a serious animation camera which he patented. With the device, his company created "Snow White".
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7981418 | Predicting response to a HER inhibitor The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ova... | 07/19/2011 |
| 7976838 | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TN... | 07/12/2011 |
| 7879325 | HER2 antibody composition A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses... | 02/01/2011 |
| 7862817 | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies. ... | 01/04/2011 |
| 7741072 | Polypeptide variants A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered eff... | 06/22/2010 |
| 7708994 | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TN... | 05/04/2010 |
| 7618631 | Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and EGFR-targeted drugs. ... | 11/17/2009 |
| 7601335 | Pretreatment of a biological sample from an autoimmune disease subject The present application describes a method for pretreating a biological sample from an autoimmune disease subject in order to avoid interference, especially where the sample is to be subjected to a cell-based biological activity assay, such as a neutralizing antibod... | 10/13/2009 |
| 7560111 | HER2 antibody composition A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses... | 07/14/2009 |
| 7537931 | Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies. ... | 05/26/2009 |
| 7501122 | Treatment with anti-ErbB2 antibody combinations The present application describes methods for treating ErbB-expressing cancer with anti-ErbB2 antibody combinations. ... | 03/10/2009 |
| 7498030 | Treatment with anti-ErbB2 antibodies and anti-hormonal compounds The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and anti-hormonal compounds, such as anti-estrogens. ... | 03/03/2009 |
| 7485302 | Treatment with anti-ErbB2 antibodies and chemotherapeutic agents The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and chemotherapeutic agents. ... | 02/03/2009 |
| 7452539 | Stabilizing polypeptides which have been exposed to urea Methods for stabilizing polypeptides, such as anti-HER2 antibodies, which have been exposed to urea. ... | 11/18/2008 |
| 7449184 | Fixed dosing of HER antibodies The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab. ... | 11/11/2008 |
| 7416727 | Polypeptide variants with altered effector function The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc reg... | 08/26/2008 |
| 7371826 | Polypeptide variants with altered effector function The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc reg... | 05/13/2008 |
| 7371379 | Dosages for treatment with anti-ErbB2 antibodies The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody. | 05/13/2008 |
| 7371376 | Anti-ErbB2 antibodies Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described. ... | 05/13/2008 |
| 7364731 | Polypeptide variants A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326,327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effe... | 04/29/2008 |
| 7335742 | Polypeptide variants with altered effector function The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc reg... | 02/26/2008 |
| 7332581 | Polypeptide variants with altered effector function The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc reg... | 02/19/2008 |
| 7297775 | Polypeptide variants A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered eff... | 11/20/2007 |
| 7183387 | Polypeptide variants with altered effector function The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc reg... | 02/27/2007 |
| 7122637 | Polypeptide variants with altered effector function The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc reg... | 10/17/2006 |
| 7074404 | Protein purification A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one or more contaminants. ... | 07/11/2006 |
| 7060268 | Protein formulation A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibod... | 06/13/2006 |
| 6949245 | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies. ... | 09/27/2005 |
| 6821515 | Protein formulation A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibod... | 11/23/2004 |
| 6800738 | Method for making humanized antibodies Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided. ... | 10/05/2004 |
| 6797814 | Protein purification A method for purifying proteins by Protein A chromatography is described which comprises the steps of: (a) adsorbing the protein to Protein A immobilized on a solid phase comprising silica or glass; (b) removing contaminants bound to the solid phase by washing the s... | 09/28/2004 |
| 6737056 | Polypeptide variants with altered effector function The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc reg... | 05/18/2004 |
| 6719971 | Method for making humanized antibodies Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided. ... | 04/13/2004 |
| 6685940 | Protein formulation A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-H... | 02/03/2004 |
| 6647565 | Drainage surface construction This application describes a method of constructing a surface for drainage, and a kit of parts forming components required to produce such a drainage surface.... | 11/18/2003 |
| 6639055 | Method for making humanized antibodies Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.... | 10/28/2003 |
| 6627196 | Dosages for treatment with anti-ErbB2 antibodies The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 ... | 09/30/2003 |
| 6538124 | Polypeptide variants Isolated nucleic acid, vectors and host cells encoding antibody or immunoadhesin variants, as well as a process for producing the variants. The variants comprise a human IgG Fc region with amino acid substitution(s) therein, and display altered C1q bindin... | 03/25/2003 |
| 6528624 | Polypeptide variants A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display ... | 03/04/2003 |
| 6500941 | Gamma-heregulin A novel member of the heregulin superfamily has been identified which is designated "γ-HRG". This molecule, secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of th... | 12/31/2002 |
